prompt sheet that is provided to breast cancer patients at UCSF to stimulate questions to ask the doctor is available on the site, and covers areas such as treatment options, goals of treatment, the impact of each choice, and barriers that might exist.

"/> Cure Magazine
ADVERTISEMENT

Web Exclusive: Questions to Ask Your Doctor

With so many options, patients need specific information from their physicians in order to make decisions that fit their goals and situation.

Jeffrey Belkora, PhD, director of Breast Care Center Decision Services at the University of California, San Francisco, hosts Guidesmith, a public interest website that “focuses on how you can use leadership, teamwork, and decision making skills and tools to guide yourself, or someone else, through high-stakes situations.”

The prompt sheet that is provided to breast cancer patients at UCSF to stimulate questions to ask the doctor is available on the site, and covers areas such as treatment options, goals of treatment, the impact of each choice, and barriers that might exist.

$author$
PUBLISHED MONDAY, SEPTEMBER 8, 2008
With so many options, patients need specific information from their physicians in order to make decisions that fit their goals and situation.

Jeffrey Belkora, PhD, director of Breast Care Center Decision Services at the University of California, San Francisco, hosts Guidesmith, a public interest website that “focuses on how you can use leadership, teamwork, and decision making skills and tools to guide yourself, or someone else, through high-stakes situations.”

The prompt sheet that is provided to breast cancer patients at UCSF to stimulate questions to ask the doctor is available on the site, and covers areas such as treatment options, goals of treatment, the impact of each choice, and barriers that might exist.

ADVERTISEMENT
Related Articles
Ovarian Suppression Emerges as Option for Younger, Premenopausal Breast Cancer Patients
BY JASON M. BRODERICK
Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.
Several Cancer Therapies Up for FDA Review in 2015
BY ANITA T. SHAFFER
The Food and Drug Administration’s calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Study Shows Women with Stage 1 HER2-Positive Breast Cancers Could Benefit from Herceptin
BY CHRISTINA IZZO
Results of a phase 2 study showed that women with small, stage 1 HER2-positive breast cancer who received a combination of lower-intensity chemotherapy and Herceptin following surgery were highly unlikely to have a recurrence.
Overcoming the Mental Battle of  Metastatic Cancer
The mental challenges of having stage 4 breast cancer are just as overwhelming as the physical ones.
Firstline Kadcyla Results Disappointing in HER2-Positive Metastatic Breast Cancer Trial
Two HER2-targeting regimens anchored by Kadcyla (T-DM1) failed to outperform the standard strategy of Herceptin plus chemotherapy in women newly diagnosed with advanced HER2-positive breast cancer.
Related Videos
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Breast Oncologist Beth Overmoyer Explains Results of Ovarian Suppression
Beth Overmoyer, a breast oncologist at Dana-Farber Cancer Institute, speaks on the results of the SOFT trial and its potential impact on young women with hormone receptor-positive breast cancer.
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
Follow Up Study Data Draws Attention to Benefit, Side Effects of Adjuvant Chemotherapy in Breast Cancer
Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$